Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 15, 2009


Title: Composition for Suppressing Expression of Target Gene

Number: 20090011003

Filed: Oct. 24, 2005 PCT Filed: Oct. 24, 2005

Lead Inventor: Masahiro Yamauchi, Kyowa Hakko Kogyo

According to the patent application's abstract, the invention comprises a "composition for suppressing the expression of a target gene and the like." Specifically, the invention is "a composition, comprising an RNA-encapsulated liposome [made of] complex particles comprising … a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles."

The components of the lipid membrane "can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible," the abstract adds.

Title: Short Interfering RNA and microRNA Compounds, and Methods of Designing, Making, and Using the Same

Number: 20090012016

Filed: Oct. 22, 2004 PCT Filed: Oct. 22, 2004

Lead Inventor: Zissimos Mourelatos, University of Pennsylvania

The invention, the patent application's abstract states, comprises "methods of identifying, designing, and synthesizing uniquely targeting siRNA nucleotide sequences for a target mRNA sequence of a target species … [as well as] methods of identifying, designing, and synthesizing miRNA nucleotide sequences that does not function as a siRNA nucleotide sequence for mRNA of a target species."

The patent application also claims a "method of inhibiting expression of a target mRNA molecule … siRNA molecules … [and] miRNA molecules that do not function as siRNA nucleotide sequences for mRNA of a target species," according to the abstract.

Title: Delivery of siRNA by Neutral Lipid Compositions

Number: 20090012021

Filed: April 17, 2006 PCT Filed: April 17, 2006

Lead Inventor: Anil Sood, MD Anderson Cancer Center

The invention "relates to the fields of molecular biology and drug delivery," the patent application's abstract states. "In certain embodiments, the … invention provides methods for the delivery of a [short interfering nucleic acid] to a cell via a neutral liposome. These methods may be used to treat a disease, such as cancer."

Title: Hybrid Interfering RNA

Number: 20090012022

Filed: May 24, 2006 PCT Filed: May 24, 2006

Lead Inventor: Josephine Anne Milner, University of York

"The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single-stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions," the patent application's abstract states.

Title: RNAi-Mediated Inhibition of HTRA1 for Treatment of Macular Degeneration

Number: 20090012030

Filed: July 1, 2008

Lead Inventor: Jon Chatterton, Alcon

"RNA interference is provided for inhibition of HTRA1 mRNA expression for treating patients with an HTRA1-mediated ocular disorder," the patent application's abstract states. "In particular, methods are provided for treating age-related macular degeneration and using interfering RNA molecules that attenuate expression of HTRA1 in patients having AMD or at risk of developing AMD."

Title: System and Method for Identification of microRNA Target Sites and Corresponding Targeting microRNA Sequences

Number: 20090012720

Filed: June 9, 2008

Lead Inventor: Tien Huynh, IBM

The invention, the patent application's abstract states, comprises "a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA will bind thereto.

"For example, in one aspect of the invention, a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto is comprised of the following steps: one or more patterns are generated by processing a collection of known mature microRNA sequences; the reverse complement of each generated patter is then computed; one or more attributes are then assigned to the reverse complement of the one or more generated patterns," the abstract states.

Next in the process, "the one or more patterns that correspond to a reverse complement having one or more assigned attributes that satisfy at least one criterion are thereafter sub-selected," the abstract adds. "Each sub-selected pattern is then used to analyze the nucleotide sequence, such that a determination is made whether the nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto."

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.